These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma. Xu F; Li H; Sun Y Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694 [TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Cheng M; Ott GR Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193 [TBL] [Abstract][Full Text] [Related]
8. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Morales La Madrid A; Campbell N; Smith S; Cohn SL; Salgia R Target Oncol; 2012 Sep; 7(3):199-210. PubMed ID: 22968692 [TBL] [Abstract][Full Text] [Related]
9. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728 [TBL] [Abstract][Full Text] [Related]
10. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404 [TBL] [Abstract][Full Text] [Related]
11. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658 [TBL] [Abstract][Full Text] [Related]